2023
Evaluation of potential instruments for quantifying necrobiosis lipoidica severity via physician evaluation and patient-reported outcomes
Hashemi D, Nelson C, Nyberg M, Das M, Rosenbach M. Evaluation of potential instruments for quantifying necrobiosis lipoidica severity via physician evaluation and patient-reported outcomes. Journal Of The American Academy Of Dermatology 2023, 89: 1305-1306. PMID: 37633461, DOI: 10.1016/j.jaad.2023.08.048.Peer-Reviewed Original ResearchDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsCutaneous adverse reactionsSystemic symptomsDrug reactionsAdverse reactionsDifferential diagnosisDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromeDiHS/DRESSVisceral organ involvementSteroid-sparing agentCornerstone of managementFirst-line therapyEvidence-based overviewSystemic corticosteroidsHypersensitivity syndromeImmediate discontinuationOrgan involvementRisk stratificationAutoimmune diseasesAdjunctive testNeoplastic disordersDiagnostic criteriaLongitudinal evaluationDiagnosisDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. Journal Of The American Academy Of Dermatology 2023, 90: 885-908. PMID: 37516359, DOI: 10.1016/j.jaad.2023.02.072.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsDiHS/DRESSClinicopathological featuresSystemic symptomsDrug reactionsDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromePart I. EpidemiologyVisceral organ involvementCutaneous adverse reactionsRisk of relapseHypersensitivity syndromeOrgan involvementI. EpidemiologyOrgan dysfunctionSignificant morbidityAutoimmune diseasesAdverse reactionsDrug exposureT cellsCommon triggerImmune systemPathogenesisEosinophiliaMedical education activities1548 Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with sweet syndrome
Bhattacharya S, Basu S, Sheng E, Wei J, Kersh A, Nelson C, Bryer J, Ashchyan H, Steele K, Forrestel A, Seykora J, Micheletti R, James W, Rosenbach M, Leung T. 1548 Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with sweet syndrome. Journal Of Investigative Dermatology 2023, 143: s266. DOI: 10.1016/j.jid.2023.03.1566.Peer-Reviewed Original ResearchAssessing the Discriminatory Ability of Diagnostic Criteria for Ulcerative Pyoderma Gangrenosum and Its Mimickers
Ji-Xu A, Liakos W, Merleev A, Brüggen M, Nelson C. Assessing the Discriminatory Ability of Diagnostic Criteria for Ulcerative Pyoderma Gangrenosum and Its Mimickers. JAMA Dermatology 2023, 159: 337-338. PMID: 36652229, PMCID: PMC9857708, DOI: 10.1001/jamadermatol.2022.5978.Peer-Reviewed Original ResearchIdentification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome
Bhattacharya S, Basu S, Sheng E, Murphy C, Wei J, Kersh A, Nelson C, Bryer J, Ashchyan H, Steele K, Forrestel A, Seykora J, Micheletti R, James W, Rosenbach M, Leung T. Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome. Journal Of Clinical Investigation 2023, 133: e162137. PMID: 36355435, PMCID: PMC9797331, DOI: 10.1172/jci162137.Peer-Reviewed Original ResearchConceptsSteroid-sparing agentSweet's syndromeInflammatory diseasesCorticosteroid-related side effectsElevated IL-1Febrile neutrophilic dermatosisDramatic therapeutic responseReceptor 1 antagonistNeutrophil respiratory burstMultiorgan inflammatory diseasePersonalized medicine approachPI3K/AktSuccessful clinical interventionNeutrophilic dermatosisFrontline therapyRefractory casesNeutrophilic infiltrateBlood countIL-1βNeutrophil functionNeutrophil migrationTherapeutic responseLiver enzymesClinical challengeIL-1Caroline Nelson Dermatology: Comprehensive Board Review and Practice Examinations
Lippincott Williams & WilkinsBooks
2022
Reducing the carbon footprint of travel to an international dermatology conference: a case study of the Medical Dermatology Society's Carbon Footprint Program
Belzer A, Rosenbach M, Parker E, Barbieri J, Nelson C. Reducing the carbon footprint of travel to an international dermatology conference: a case study of the Medical Dermatology Society's Carbon Footprint Program. International Journal Of Dermatology 2022, 62: e377-e379. PMID: 36371718, DOI: 10.1111/ijd.16497.Peer-Reviewed Original ResearchLB1040 Treatment of sweet syndrome by molecular identification of PIK3R1 mutation
Bhattacharya S, Sheng E, Murphy C, Wei J, Kersh A, Nelson C, Bryer J, Ashchyan H, Steele K, Forrestel A, Seykora J, Micheletti R, James W, Rosenbach M, Leung T. LB1040 Treatment of sweet syndrome by molecular identification of PIK3R1 mutation. Journal Of Investigative Dermatology 2022, 142: b37. DOI: 10.1016/j.jid.2022.05.1078.Peer-Reviewed Original Research
2020
15995 Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States
Bui A, Singer S, Tkachenko E, Sharma P, Nelson C, LeBoeuf N, Mostaghimi A. 15995 Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States. Journal Of The American Academy Of Dermatology 2020, 83: ab166. DOI: 10.1016/j.jaad.2020.06.754.Peer-Reviewed Original Research18847 A case-control study evaluating impact on tumor response and Survival outcomes of bullous pemphigoid following anti–PD-1 therapy
Singer S, Nelson C, Chen T, Eberly-Puelo A, Lian C, Wei E, Giobbe-Hurder A, Mostaghimi A, LeBoeuf N. 18847 A case-control study evaluating impact on tumor response and Survival outcomes of bullous pemphigoid following anti–PD-1 therapy. Journal Of The American Academy Of Dermatology 2020, 83: ab108. DOI: 10.1016/j.jaad.2020.06.519.Peer-Reviewed Original ResearchGeographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States
Singer S, Tkachenko E, Sharma P, Nelson C, Mostaghimi A, LeBoeuf NR. Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States. Journal Of The American Academy Of Dermatology 2020, 85: 1248-1252. PMID: 32610170, DOI: 10.1016/j.jaad.2020.06.073.Peer-Reviewed Original ResearchA detailed analysis of the distribution, morphology, and histopathology of complex purpura in hospitalized patients: A case series of 68 patients
Gehlhausen JR, Wetter DA, Nelson C, Ramachandran S, McNiff JM, Ko CJ. A detailed analysis of the distribution, morphology, and histopathology of complex purpura in hospitalized patients: A case series of 68 patients. Journal Of The American Academy Of Dermatology 2020, 84: 1188-1196. PMID: 32376433, DOI: 10.1016/j.jaad.2020.04.149.Peer-Reviewed Original ResearchConceptsSmall vessel vasculitisLeukocytoclastic vasculitisMicrovascular occlusionIgA vasculitisCase seriesCommon diagnosisSystemic diseaseDermatologic consultationHigh mortalityTertiary care centerMajority of patientsMedium vessel vasculitisBiopsy findingsHospitalized patientsCare centerRetrospective natureVasculitisDifferential diagnosisInpatient consultationsPurpuraClinical morphologyDiagnostic utilityPatientsInpatientsSuperficial vesselsPatient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening
Nelson CA, Pérez-Chada LM, Creadore A, Li SJ, Lo K, Manjaly P, Pournamdari AB, Tkachenko E, Barbieri JS, Ko JM, Menon AV, Hartman RI, Mostaghimi A. Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening. JAMA Dermatology 2020, 156: 501-512. PMID: 32159733, PMCID: PMC7066525, DOI: 10.1001/jamadermatol.2019.5014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedArtificial IntelligenceBiopsyEarly Detection of CancerFemaleGrounded TheoryHealth Services AccessibilityHumansInterviews as TopicMaleMass ScreeningMelanomaMiddle AgedObserver VariationPatient Acceptance of Health CarePhysician-Patient RelationsQualitative ResearchReproducibility of ResultsSkin NeoplasmsConceptsSkin cancer screeningCancer screeningSkin cancerPatient's perspectiveAccurate diagnosisDana-Farber Cancer InstituteGeneral dermatology clinicNonmelanoma skin cancerHistory of melanomaHealth care accessPhysician-patient relationshipMelanoma clinicDermatology clinicWomen's HospitalPatient anxietySkin lesionsMAIN OUTCOMECare accessCancer InstitutePatientsQualitative studyCancerHealth careClinicHospitalTeledermatology in the era of COVID-19: Experience of an academic department of dermatology
Perkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the era of COVID-19: Experience of an academic department of dermatology. Journal Of The American Academy Of Dermatology 2020, 83: e43-e44. PMID: 32305442, PMCID: PMC7162755, DOI: 10.1016/j.jaad.2020.04.048.Peer-Reviewed Original ResearchA Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria
Nelson CA, Zhong CS, Hashemi DA, Ashchyan HJ, Brown-Joel Z, Noe MH, Imadojemu S, Micheletti RG, Vleugels RA, Wanat KA, Rosenbach M, Mostaghimi A. A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatology 2020, 156: 270-279. PMID: 31940000, PMCID: PMC6990734, DOI: 10.1001/jamadermatol.2019.4221.Peer-Reviewed Original ResearchConceptsMulticenter cross-sectional studyNecrobiotic xanthogranulomaCross-sectional studyPlasma cell dyscrasiaDiagnostic criteriaMulticenter cohortMalignant conditionsConsensus exerciseSystematic reviewPeriorbital distributionLymphoproliferative disordersCutaneous lesionsMultiple myelomaMinor criteriaBetter treatment response rateDiagnosis of NXGTertiary academic referral centerNon-Langerhans cell histiocytosisAcademic referral centerTreatment response ratesPennsylvania Health SystemMassachusetts General HospitalBoard-certified dermatologistsIntralesional triamcinoloneIntravenous immunoglobulinBullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes
Nelson CA, Singer S, Chen T, Puleo AE, Lian CG, Wei EX, Giobbie-Hurder A, Mostaghimi A, LeBoeuf NR. Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes. Journal Of The American Academy Of Dermatology 2020, 87: 1400-1402. PMID: 31931083, DOI: 10.1016/j.jaad.2019.12.068.Peer-Reviewed Original Research
2019
Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes
Hashemi DA, Brown-Joel ZO, Tkachenko E, Nelson CA, Noe MH, Imadojemu S, Vleugels RA, Mostaghimi A, Wanat KA, Rosenbach M. Clinical Features and Comorbidities of Patients With Necrobiosis Lipoidica With or Without Diabetes. JAMA Dermatology 2019, 155: 455-459. PMID: 30785603, PMCID: PMC6523472, DOI: 10.1001/jamadermatol.2018.5635.Peer-Reviewed Original ResearchConceptsNecrobiosis lipoidicaClinical featuresThyroid diseaseDiagnosis of NLRare granulomatous conditionComorbidities of patientsMulticenter retrospective reviewElevated blood glucosePennsylvania Health SystemMassachusetts General HospitalNL lesionsNotable comorbiditiesMedical comorbiditiesMedian hemoglobinPatient demographicsMedian ageRetrospective reviewEpidemiologic characteristicsPathophysiologic characteristicsBiopsy statusGranulomatous conditionsCase reportFemale sexBlood glucoseRisk factors
2018
Human‐computer symbiosis: enhancing dermatologic care while preserving the art of healing
Nelson CA, Kovarik CL, Barbieri JS. Human‐computer symbiosis: enhancing dermatologic care while preserving the art of healing. International Journal Of Dermatology 2018, 57: 1015-1016. PMID: 29873395, DOI: 10.1111/ijd.14071.Peer-Reviewed Original ResearchNeutrophilic dermatoses Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease
Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. Journal Of The American Academy Of Dermatology 2018, 79: 987-1006. PMID: 29653210, DOI: 10.1016/j.jaad.2017.11.064.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntineoplastic AgentsAutoimmune DiseasesBehcet SyndromeChemotaxis, LeukocyteCytokinesDermisDiagnosis, DifferentialDrug EruptionsEpidermisEthnicityGenetic Predisposition to DiseaseHidradenitisHumansImmunity, InnateImmunosuppressive AgentsInflammationNeoplasmsNeutrophilsSweet SyndromeVasculitisConceptsNeutrophilic eccrine hidradenitisNeutrophilic dermatosisSweet's syndromeBehçet's diseaseInflammatory skin disorderSignificant patient morbidityUnique clinical featuresMedical education seriesSystemic corticosteroidsBiologic agentsClinical featuresNeutrophilic infiltrateCutaneous lesionsHistopathologic featuresPatient morbidityTherapeutic modalitiesNeoplastic processSkin disordersDermatosesHeterogeneous groupDiseaseDiagnosisHidradenitisDisordersSyndrome